Patients with systemic mastocytosis (ECNM) stratified according to lactate dehydrogenase levels
| . | LDH ≥260 U/L . | LDH <260 U/L . | P value . |
|---|---|---|---|
| Number of patients at diagnosis, n (%) | 236 (12) | 1715 (88) | |
| Age, years; median (range) | 55 (18-90) | 50 (5-87) | <.001 |
| Male, n (%) | 149 (63) | 789 (46) | <.001 |
| C-findings | |||
| Hemoglobin, g/dL; median (range) | 13 (4-18) | 14 (4-18) | <.001 |
| <10 g/dL, n (%) | 44 (19) | 107 (6) | <.001 |
| Platelets, ×109/L; median (range) | 227 (0-958) | 251 (5-893) | NS |
| <100 ×109/L, n (%) | 51 (22) | 141 (8) | <.001 |
| ANC, ×109/L; median (range) | 4 (0-9) | 4 (0-76) | <.001 |
| <1 ×109/L, n (%) | 7 (3) | 20 (1) | .025 |
| Alkaline phosphatase, U/L; median (range) | 84 (34-1696) | 77 (20-1407) | .001 |
| >150 U/L, n (%) | 58 (27) | 206 (13) | <.001 |
| Albumin level, g/L; median (range) | 41 (16-57) | 44 (20-57) | <.001 |
| <34 g/L, n (%) | 26 (14) | 58 (4) | <.001 |
| Ascites, n (%) | 23 (10) | 97 (6) | .020 |
| Portal hypertension, n (%) | 7 (3) | 42 (3) | NS |
| Weight loss (>10% over last 6 months), n (%) | 44 (19) | 172 (10) | <.001 |
| Osteolytic lesions, n (%) | 7 (3) | 47 (3) | NS |
| B-findings | |||
| Dysmyelopoiesis, n (%) | 64 (28) | 206 (13) | <.001 |
| BM MC infiltration, %; median (range) | 15 (1-90) | 10 (0-100) | NS |
| Serum tryptase level, μg/L; median (range) | 43 (1-4530) | 36 (2-4980) | NS |
| >125 μg/L, n (%) | 59 (27) | 330 (20) | .020 |
| Splenomegaly, n (%) | 65 (28) | 291 (17) | <.001 |
| Hepatomegaly, n (%) | 58 (234) | 249 (1662) | <.001 |
| Lymphadenopathy, n (%) | 32 (210) | 148 (10) | .009 |
| Other relevant findings | |||
| Leukocytes, ×109/L; median (range) | 7.7 (0.6-129.3) | 6.7 (1.0-97.3) | <.001 |
| >16 ×109/L, n (%) | 47 (20) | 55 (3) | <.001 |
| Monocytes, ×109/L; median (range) | 0.5 (0.0-18.7) | 0.4 (0.0-8.2) | <.001 |
| >0.8 ×109/L | 44 (58) | 16 (12) | <.001 |
| Eosinophils, ×109/L; median (range) | 0.2 (0.0-35.0) | 0.1 (0.0-18.5) | .006 |
| >1.5 ×109/L | 17 (23) | 6 (4) | <.001 |
| KIT D816V positive, n (%) | 163 (82) | 1308 (88) | .029 |
| BM MC burden in smears, %; median (range) | 5 (0-88) | 2 (0-100) | .041 |
| Outcome | |||
| Follow-up, years; median (range) | 1.34 (0.0-22.3) | 2.1 (0.0-28.6) | NS |
| Death, n (%) | 65 (30) | 177 (14) | <.001 |
| . | LDH ≥260 U/L . | LDH <260 U/L . | P value . |
|---|---|---|---|
| Number of patients at diagnosis, n (%) | 236 (12) | 1715 (88) | |
| Age, years; median (range) | 55 (18-90) | 50 (5-87) | <.001 |
| Male, n (%) | 149 (63) | 789 (46) | <.001 |
| C-findings | |||
| Hemoglobin, g/dL; median (range) | 13 (4-18) | 14 (4-18) | <.001 |
| <10 g/dL, n (%) | 44 (19) | 107 (6) | <.001 |
| Platelets, ×109/L; median (range) | 227 (0-958) | 251 (5-893) | NS |
| <100 ×109/L, n (%) | 51 (22) | 141 (8) | <.001 |
| ANC, ×109/L; median (range) | 4 (0-9) | 4 (0-76) | <.001 |
| <1 ×109/L, n (%) | 7 (3) | 20 (1) | .025 |
| Alkaline phosphatase, U/L; median (range) | 84 (34-1696) | 77 (20-1407) | .001 |
| >150 U/L, n (%) | 58 (27) | 206 (13) | <.001 |
| Albumin level, g/L; median (range) | 41 (16-57) | 44 (20-57) | <.001 |
| <34 g/L, n (%) | 26 (14) | 58 (4) | <.001 |
| Ascites, n (%) | 23 (10) | 97 (6) | .020 |
| Portal hypertension, n (%) | 7 (3) | 42 (3) | NS |
| Weight loss (>10% over last 6 months), n (%) | 44 (19) | 172 (10) | <.001 |
| Osteolytic lesions, n (%) | 7 (3) | 47 (3) | NS |
| B-findings | |||
| Dysmyelopoiesis, n (%) | 64 (28) | 206 (13) | <.001 |
| BM MC infiltration, %; median (range) | 15 (1-90) | 10 (0-100) | NS |
| Serum tryptase level, μg/L; median (range) | 43 (1-4530) | 36 (2-4980) | NS |
| >125 μg/L, n (%) | 59 (27) | 330 (20) | .020 |
| Splenomegaly, n (%) | 65 (28) | 291 (17) | <.001 |
| Hepatomegaly, n (%) | 58 (234) | 249 (1662) | <.001 |
| Lymphadenopathy, n (%) | 32 (210) | 148 (10) | .009 |
| Other relevant findings | |||
| Leukocytes, ×109/L; median (range) | 7.7 (0.6-129.3) | 6.7 (1.0-97.3) | <.001 |
| >16 ×109/L, n (%) | 47 (20) | 55 (3) | <.001 |
| Monocytes, ×109/L; median (range) | 0.5 (0.0-18.7) | 0.4 (0.0-8.2) | <.001 |
| >0.8 ×109/L | 44 (58) | 16 (12) | <.001 |
| Eosinophils, ×109/L; median (range) | 0.2 (0.0-35.0) | 0.1 (0.0-18.5) | .006 |
| >1.5 ×109/L | 17 (23) | 6 (4) | <.001 |
| KIT D816V positive, n (%) | 163 (82) | 1308 (88) | .029 |
| BM MC burden in smears, %; median (range) | 5 (0-88) | 2 (0-100) | .041 |
| Outcome | |||
| Follow-up, years; median (range) | 1.34 (0.0-22.3) | 2.1 (0.0-28.6) | NS |
| Death, n (%) | 65 (30) | 177 (14) | <.001 |
A total of 1951 patients with systemic mastocytosis from the ECNM database were stratified according to lactate dehydrogenase levels of ≥260 U/L or <260 U/L.
ANC, absolute neutrophil count; BM, bone marrow; MC, mast cell; NS, not significant.